Navigation Links
Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
Date:6/22/2013

CHICAGO, June 22, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from an additional analysis of Phase II clinical data for LY2605541, an investigational novel basal insulin analog. The analysis provides more in-depth information about the reductions in required prandial (mealtime) insulin in LY2605541-treated patients compared to those treated with insulin glargine.[1] These findings are being presented at the 73rd American Diabetes Association Scientific Sessions® in Chicago, June 21–25, 2013.

Initial clinical data from a Phase II study showed that LY2605541-treated patients with type 1 diabetes had greater improvements in glycemic control along with reduced mealtime insulin doses compared to insulin glargine-treated patients.[2] Results from this additional analysis showed that among those who completed the Phase II study, which included eight weeks of treatment with LY2605541 and eight weeks of insulin glargine, LY2605541 led to significantly lower average blood glucose levels (143.1 mg/dL vs. 151.7 mg/dL) with statistically significantly less mealtime insulin per day compared to insulin glargine. The reduced mealtime insulin use was found per day and across all major meals, including:

  • breakfast (-0.9 +/- 0.4 International Units (IU) [13.7 percent reduction]),
  • lunch (-1.4 +/- 0.4 IU [18.6 percent reduction]),
  • dinner (-2.0 +/- 0.4 IU [22.4 percent reduction]), and 
  • total daily dose (-4.3 +/- 1.5 IU) [20.7 percent reduction in units]).[1]

LY2605541-treated patients had a statistically higher overall hypoglycemia rate (blood glucose less than or equal to 70 mg/dL) compared to insulin glargine (9.2 vs. 8.1 events/30 days) but a statistically lower rate
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy
2. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
4. Six-Year Follow-Up Data for SPRYCEL®? (dasatinib) 100 mg Once Daily Demonstrates 71 Percent Overall Survival in Patients with Chronic-Phase Chronic Myeloid Leukaemia Resistant or Intolerant to Imatinib
5. Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulfonylurea in adults with type 2 diabetes
6. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
7. Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine
8. Safinamide Phase III Study Results Presented at 2013 MDS Meeting
9. Adamas Pharmaceuticals Presents Positive Phase 2/3 Results For ADS-5102 For The Treatment Of Levodopa-Induced Dyskinesia (LID) In Parkinsons Disease
10. Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
11. AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014   Auxilium Pharmaceuticals , Inc. (NASDAQ: ... company, today announced that the Company will release results ... 7, 2014 before the opening of the U.S. financial ... that day at 8:30 a.m. ET to discuss results ... presentation slides to be used during the call will ...
(Date:7/31/2014)... , July 31, 2014  Decision ... changes brought about by the Affordable Care ... and prescribing of pharmaceutical therapies. The ACA ... beneficiaries through new regulations and expanded access ... in the health exchanges—state-based marketplaces set up ...
(Date:7/31/2014)... 2014 Touro University California,s College of Pharmacy ... the recipient of a $150,000 grant by the Joseph ... to increase research and classroom space on its campus. ... the study of health sciences, and will help us ... interests of our students," said Shelley Berkley , ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 2Auxilium Pharmaceuticals, Inc. To Announce Second Quarter 2014 Results On August 7, 2014 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Touro University California Garners Grant From Long Foundation 2
... -- Global Information, Inc. (GII) presents " Computed Tomography ... Market Forecasts to 2017 " by GlobalData.  ... global Computed Tomography (CT) systems market to be worth ... systems and low-dose CT systems, the market is forecast ...
... -- Physicians, Capital Investments, LLC (PCI/the Company) a leader ... is pleased to announce that Becker,s ASC Review has ... in the ASC Industry to Know." This publication recognizes ... through their work with ASC-related companies, surgery centers and ...
Cached Medicine Technology:GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market 2GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market 3GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market 4Physicians' Capital Investments Announces Pedro Vergne-Marini, MD Named to Becker's ASC Review "350 People in the ASC Industry to Know" 2Physicians' Capital Investments Announces Pedro Vergne-Marini, MD Named to Becker's ASC Review "350 People in the ASC Industry to Know" 3Physicians' Capital Investments Announces Pedro Vergne-Marini, MD Named to Becker's ASC Review "350 People in the ASC Industry to Know" 4
(Date:8/1/2014)... at the Institute of Bioengineering and Nanotechnology (IBN), ... Singapore (NCCS) have co-developed the first molecular test ... in kidney cancer patients. This breakthrough was recently ... top urology journal. , According to IBN ... our expertise in molecular diagnostics and cancer research, ...
(Date:8/1/2014)... St. Christopher's Hospital for Children announced that they ... with Ed Begley Jr, airing later this year 2014, ... St. Christopher's Hospital for Children offers a wide range ... 21 years of age. With over 220 pediatric specialists, ... autism and childhood obesity. , “St. Christopher’s is ...
(Date:8/1/2014)... Jordan, Utah (PRWEB) August 01, 2014 ... company MonaVie, who completes its 500th week of paying ... since the company was founded in January 2005 total ... countries throughout the world. The company pays commissions in ... HUF, ILS, JPY, MYR, MXN, NZD, PLN, USD, SGD, ...
(Date:8/1/2014)... BellasDress has recently showcased its beautifully ... season’s gorgeous styles. The company’s lot of hot styles, ... outfits, one shoulder chiffon outfits and high low outfits. ... elegant purple prom dresses. As one of the most ... product quality. Thus, all its items are of superb ...
(Date:8/1/2014)... CentraComm, a leading managed IT security ... the Pure Storage® Authorized Reseller program. , ... experience designed to meet the rigorous resiliency, scalability, ... diverse markets, and for a variety of high ... years. , The Pure Storage FlashArray was ...
Breaking Medicine News(10 mins):Health News:Taking the guesswork out of cancer therapy 2Health News:Taking the guesswork out of cancer therapy 3Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 2Health News:Innovations with Ed Begley, Jr. to Feature St. Christopher's Hospital for Children in Upcoming Episode 3Health News:MonaVie Records 500th Commission Week, Having Paid Out More Than $1.4B in Distributor Commissions 2Health News:BellasDress Creates Must-have Purple Prom Dresses for Prom Attendees 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 2Health News:CentraComm Accepts Pure Storage Authorized Reseller Partner Invitation 3
... , ... Products at E3 Expo To Show Off Consumer Market Appeal and Wellness Benefits for Gamers ... Los Angeles, CA (Vocus) ... innovative musical instruments and music software to enable people of all ages and skill levels ...
... ... of your control environment, SAS 70 reports have become a credible marketing tool to ... ... is a leading provider that specializes solely in SAS 70 readiness reviews, SAS 70 Type ...
... promising. Sorafenib is used for advanced liver and kidney ... stem cells in pancreatic cancer. The team led by ... Molecular Oncosurgery, a group of the Department of Surgery ... W. Bchler) in cooperation with the German Cancer Research ...
... with the right information, physicians can play a stronger ... drugs proven to prevent asthma attacks, according to researchers ... finds patients are more likely to routinely take inhaled ... watch over their medication use and reviewed detailed electronic ...
... ... same-day healthcare appointments online. , ... Chicago, IL (PRWEB) June 15, 2010 -- ZocDoc, the website to ... metropolitan area. The company’s move was chosen by thousands of users, who were asked ...
... ... process should not be undertaken without legal representation, urges American Residential Law Group. ... Fort Lauderdale, FL ... foreclosure not to go through the mortgage modification process without viable legal help on ...
Cached Medicine News:Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 2Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 3Health News:Beamz Announces Partnership with Dynaflex International at E3 Expo 4Health News:Can a SAS 70 Audit Create a Competitive Advantage for Your Business? 2Health News:Can a SAS 70 Audit Create a Competitive Advantage for Your Business? 3Health News:Can a SAS 70 Audit Create a Competitive Advantage for Your Business? 4Health News:New combination effective against pancreatic cancer 2Health News:Study: Getting patients to take their asthma meds 2Health News:Chicago Votes for Improved Healthcare with ZocDoc 2Health News:American Residential Law Group Urges Homeowners Not to “Go It Alone” During Mortgage Modification 2
The Reusable Purse String Clamp is intended for use in the mechanical construction of a purse string suture. The clamp can be used on any part of the gastrointestinal tract except the esophagus....
... VALTRAC™ Single Use Biofragmentable Anastomosis ... end-to-end, end-to-side and side-to-side anastomosis., ... and multiple intestinal anastomoses but not ... device may be used in any ...
The Auto Suture™ EEA™ 34mm reusable stainless steel sizer has application in intestinal, colorectal and esophageal surgery to help evaluate the diameter of tubular structures....
... in the parafollicular C-cells of the thyroid ... The major action of calcitonin is to ... activity, resulting in decreased mobilization of calcium ... evident in conditions associated with high levels ...
Medicine Products: